# OnCo record nct06118333 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06118333/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06118333", "NCT06118333" ;
  schema:name "A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)"@en ;
  schema:alternateName "PANKU-NPC01"@en ;
  schema:description "A phase 3 trial of Izalontamab brengitecan, Capecitabine, Gemcitabine in nasopharyngeal carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06118333/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06118333> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-12-04" ;
  onco:cancers <https://onco.cc/cancers/nasopharyngeal/>, <https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/> ;
  onco:drugs <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/systimmune/> .